COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionTHE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at 103 - 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Amalgamation Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry Jurisdiction
ESCROW AGREEMENTEscrow Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances
Contract Type FiledMay 29th, 2024 Company IndustryTHIS AGREEMENT is being entered into by the Parties under National Policy 46-201 Escrow for Initial Public Offerings (the “Policy”) in connection with the proposed non-offering prospectus by the Issuer, an emerging issuer.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionASEP MEDICAL HOLDINGS INC., a British Columbia company, having its principal office located at 420 – 730 View Street, Victoria, British Columbia, V8W 3Y7
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Feasibility Study Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionABT INNOVATIONS INC., a company incorporated under the British Columbia Corporations Act and having its administrative offices at 200-931 Fort Street, Victoria, B.C. VBV 3K3 (“ABT”), Attention: Dr. Robert E. W. Hancock (“Provider Scientist”), Telephone: __________, E-mail: __________
OPTION AGREEMENTOption Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionTHIS AGREEMENT is dated as of May 14 , 2021 (the “Effective Date”) among ASEP Medical Inc. (the “Optionee”), Sepset Biosciences Inc. (the “Optionor”) and each of the securityholders of the Optionor listed in Schedule “A” hereto (collectively, the “Securityholders” and individually each a “Securityholder”) including without limitation CDRD Ventures Inc. (the “Creditor”). The Optionor, the Optionee and each Securityholder are referred to herein as a “Party”, and together as the “Parties”.
START-UP LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and SAFECOAT MEDICAL INCStart-Up License Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionTHE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
OPTION AGREEMENTOption Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionTHIS AGREEMENT is dated as of May 14, 2021 (the “Effective Date”) among ASEP Medical Inc. (the “Optionee”), ABT Innovations Inc. (the “Optionor”) and each of the securityholders of the Optionor listed in Schedule “A” hereto (except UBC) (collectively, the “Securityholders” and individually each a “Securityholder”). The Optionor, the Optionee and each Securityholder are referred to herein as a “Party”, and together as the “Parties”.
ContractEmployment Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionPursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as private or confidential.
EARN-IN AND OPTION AGREEMENTEarn-in and Option Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionFOR VALUABLE CONSIDERATION, the receipt and sufficiency of which is hereby acknowledged by the undersigned, the undersigned hereby:
ContractConsulting Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances
Contract Type FiledMay 29th, 2024 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as private or confidential.
CONSULTING AGREEMENTConsulting Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionWHEREAS the Company desires to obtain the benefit of the services of the Consultant, and the Consultant desires to render such services on the terms and conditions set forth;
JOINT VENTURE AND LICENSE AGREEMENTJoint Venture and License Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionNOW THEREFORE, in consideration of the mutual covenants in this Agreement and other good and valuable consideration, the receipt and sufficiency of all of which are hereby acknowledged by each Party, the Parties covenant and agree as follows:
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Consulting Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionWHEREAS the Company desires to obtain the benefit of the services of the Consultant, and the Consultant desires to render such services on the terms and conditions set forth;
EMPLOYEE EMPLOYMENT AGREEMENTEmployee Employment Agreement • May 29th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledMay 29th, 2024 Company Industry JurisdictionASEP MEDICAL HOLDINGS INC., a British Columbia company, having its principal office located at 420 – 730 View Street, Victoria, British Columbia, V8W 3Y7